Phase 2 trial of lenvatinib and everolimus in metastatic renal cell carcinoma - European Medical Journal

Continue

Phase 2 trial of lenvatinib and everolimus in metastatic renal cell carcinoma

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, discusses the results of a phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?